Pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types - Baselga,J.; Rischin,D.; Ranson,M. (J Clin Oncol, 2002)